Recombinant Ictalurid herpesvirus 1 Protein kinase ORF15 (ORF15)

What are the structural characteristics of Ictalurid herpesvirus 1 protein kinase ORF15?

Protein kinase ORF15 is a 380-amino acid protein with a molecular weight of approximately 42.4 kDa . The full amino acid sequence begins with MAAVNWLKDE and ends with IREVATQPEH . As a viral protein kinase, ORF15 contains conserved catalytic domains typical of serine/threonine kinases, including ATP-binding sites and phosphate transfer regions. Bioinformatic analyses suggest that ORF15 likely adopts a structure similar to other viral kinases, with smaller N-terminal and larger C-terminal lobes connected by a hinge region that forms the catalytic site.

ORF15 is encoded by the Ictalurid herpesvirus 1 genome (GenBank accession: NP_041106.1) and is classified as a protein kinase based on sequence homology and predicted functional domains . Unlike some viral proteins that have clear mammalian homologs, ORF15 has unique structural features that differentiate it from host cell kinases, making it a potential target for selective antiviral strategies.

What expression systems are most effective for producing recombinant ORF15 protein?

Several expression systems can be employed for producing recombinant ORF15, each offering distinct advantages depending on research objectives:

The choice between these systems should be guided by the specific requirements of the intended research. For structural studies requiring large quantities of protein, E. coli may be preferable, while for functional studies requiring enzymatic activity, baculovirus or mammalian expression systems would be more appropriate . The baculovirus expression system has been particularly useful for viral proteins, including ORF15, as it provides a good balance between yield and post-translational modifications .

What purification strategies yield high-purity ORF15 protein suitable for enzymatic studies?

Obtaining high-purity ORF15 protein for enzymatic studies typically involves a multi-step purification strategy:

• Affinity chromatography: The primary purification step usually employs affinity tags such as His6-tag, which allows selective capture of the recombinant protein using Ni-NTA resin . This approach takes advantage of the high affinity between the histidine tag and immobilized nickel ions.

• Ion exchange chromatography: This secondary step separates proteins based on their charge properties, helping to remove contaminants with different ionic characteristics from ORF15.

• Size exclusion chromatography: As a final polishing step, this technique separates proteins based on their molecular size, yielding highly purified ORF15 suitable for enzymatic studies.

A typical optimized protocol includes cell lysis under non-denaturing conditions, clarification by centrifugation, initial capture by affinity chromatography, tag removal if necessary, and additional purification steps as required. Final purity should be verified by SDS-PAGE, with a target purity of ≥85% for enzymatic applications . To preserve activity, the purified protein should be stored in appropriate buffer conditions, typically at -80°C with glycerol as a cryoprotectant.

How can researchers verify the enzymatic activity of purified recombinant ORF15?

Verification of ORF15 kinase activity can be accomplished through several complementary approaches:

• In vitro phosphorylation assays: Using either radioactively labeled ATP (32P-ATP) or non-radioactive alternatives (ATP-γ-S), researchers can monitor phosphate transfer to known or potential substrates. Detection methods include autoradiography, mass spectrometry, or phospho-specific antibodies.

• ELISA-based assays: These quantify kinase activity through detection of specific phosphopeptides using anti-phosphotyrosine or anti-phosphoserine/threonine antibodies.

• Electrophoretic mobility shift assays: Substrate phosphorylation often results in altered electrophoretic mobility that can be detected by Western blotting or protein staining.

• Isothermal titration calorimetry (ITC): This provides thermodynamic information about ATP binding to the kinase, indicative of its functional state.

A standard protocol would involve:

• Incubation of purified ORF15 (100-500 ng) with candidate substrate (1-5 μg)

• Addition of ATP (50-100 μM) and Mg2+ (5-10 mM) in appropriate buffer

• Incubation at 30°C for 15-30 minutes

• Reaction termination with SDS-PAGE loading buffer or EDTA

• Analysis by the selected detection technique

Critical controls should include reactions without enzyme, without substrate, and with kinase inhibitors to confirm the specificity of the observed activity.

How can researchers identify cellular substrates of ORF15 during viral infection?

Identifying the cellular substrates of ORF15 requires an integrated approach combining in vitro and in vivo techniques:

• Global phosphoproteomic analysis:

  • Infect catfish cells (such as CCO cells) with wild-type CCV versus ORF15-deficient mutants

  • Extract proteins at different time points post-infection

  • Enrich phosphopeptides using titanium dioxide (TiO₂) affinity chromatography or IMAC

  • Analyze by LC-MS/MS to identify differentially phosphorylated peptides

  • Perform bioinformatic validation to identify consensus phosphorylation motifs

• In vitro kinase assays with peptide libraries:

  • Utilize peptide microarrays covering candidate phosphorylation motifs

  • Incubate with purified ORF15 and labeled ATP

  • Detect phosphorylation signals to identify preferred sequences

• Validation through site-directed mutagenesis:

  • Generate point mutants at candidate phosphorylation sites

  • Express in catfish cells followed by CCV infection

  • Analyze changes in viral replication or cellular effects

• Co-immunoprecipitation and proximity assays:

  • Use tagged versions of ORF15 (e.g., with TAP-tag)

  • Identify physically interacting proteins by mass spectrometry

  • Validate using techniques like BiFC (Bimolecular Fluorescence Complementation)

These complementary methodologies allow researchers to construct a functional interaction network between ORF15 and its cellular substrates, crucial for understanding its role in viral pathogenesis .

What role does ORF15 play in regulating the IcHV-1 replication cycle?

The role of ORF15 in regulating the Ictalurid herpesvirus 1 replication cycle can be investigated using multiple experimental approaches:

• Generation of recombinant viruses with ORF15 mutations:

  • Create null mutants, kinase-dead mutants, or point mutations in functional domains using site-directed mutagenesis and homologous recombination

  • Characterize viral phenotypes in terms of:

    • Replication kinetics (one-step growth curve)

    • Plaque formation

    • Temporal viral gene expression

    • Virion assembly and morphogenesis

• Temporal analysis of ORF15 expression and activity:

  • Detect expression by Western blot at different infection phases

  • Perform immunolocalization to determine subcellular compartments where it functions

  • Conduct kinase activity assays at different times post-infection

• Chemical and genetic inhibition:

  • Use specific kinase inhibitors to block ORF15 activity

  • Apply RNA interference (RNAi) or CRISPR-Cas9 to reduce expression

  • Evaluate impact on specific viral cycle stages:

    • Viral entry

    • Early/late gene expression

    • DNA replication

    • Virion assembly and release

These studies would provide comprehensive understanding of ORF15's regulatory role in the viral replication cycle .

How can CRISPR-Cas9 technology be applied to study ORF15 function in IcHV-1 infection models?

CRISPR-Cas9 technology offers powerful approaches for investigating ORF15 function in the context of IcHV-1 infection:

• Viral genome editing:

  • Design sgRNAs targeting specific regions of the viral ORF15 gene

  • Transfect cells with plasmids expressing Cas9 and sgRNAs along with viral DNA

  • Isolate edited viral clones through plaque assays

  • Characterize modifications by sequencing

  • Evaluate phenotypes: growth kinetics, plaque morphology, pathogenicity

• Modification of endogenous ORF15 protein:

  • Introduce tags (FLAG, HA, GFP) at N- or C-terminus for localization and interaction studies

  • Create point mutants to identify critical residues for kinase activity

  • Generate viruses with regulatable ORF15 (e.g., by fusing inducible degron domains)

• Host cell genome editing:

  • Modify potential cellular substrates of ORF15

  • Create knockout cells for factors interacting with ORF15

  • Generate reporter cell lines to monitor kinase activity

• Large-scale screening analysis:

  • Develop sgRNA libraries for screening cellular genes relevant to ORF15 function

  • Select for phenotypes related to viral replication in presence/absence of functional ORF15

A detailed protocol for editing the viral ORF15 gene would include:

• sgRNA design:

  • Identify PAM sequences (NGG) in the ORF15 gene

  • Design 3-4 sgRNAs targeting the catalytic domain

  • Evaluate specificity using bioinformatic tools

• Cloning and transfection:

  • Clone sgRNAs into expression vector (e.g., pX330)

  • Co-transfect with viral DNA in permissive cells (CCO)

  • Optionally include a repair template for HDR if specific modifications are desired

• Isolation and characterization of mutant viruses:

  • Perform limiting dilutions to isolate viral clones

  • Analyze by PCR and sequencing to confirm edits

  • Characterize phenotypically using standard virological assays

This methodology allows precise dissection of ORF15 function in the context of viral infection .

What methodological considerations are critical for developing specific inhibitors of ORF15 as potential antivirals?

Developing specific inhibitors of ORF15 as antivirals requires a systematic approach with several critical methodological considerations:

• Structural and functional characterization of the target protein:

  • Determine crystal structure or cryo-EM structure of ORF15, ideally in complex with ATP or known inhibitors

  • Map the active site and allosteric pockets through site-directed mutagenesis

  • Identify critical residues for substrate specificity versus those conserved among kinases

• Development of robust enzymatic activity assays:

  • Establish high-throughput screening (HTS) assays compatible with:

    • 384- or 1536-well plate formats

    • Non-radioactive detection (fluorescence, FRET, luminescence)

    • Low variability (Z' > 0.5)

  • Validate with broad-spectrum kinase inhibitors as controls

• Compound screening and optimization strategies:

• Specificity validation:

  • Counter-screening against panel of related human kinases

  • Selectivity assays against panel of viral and cellular kinases

  • Direct binding studies (SPR, ITC) to confirm mechanism

• Antiviral efficacy evaluation:

  • Plaque reduction or yield reduction assays

  • EC₅₀ determination in different cell lines

  • Time-of-addition analysis to identify affected viral cycle phase

  • Generation and characterization of resistant viruses to confirm target

This comprehensive approach ensures development of inhibitors with high specificity for ORF15 and potential as therapeutic agents for Ictalurid herpesvirus 1 infections .

How can researchers design experiments to determine whether ORF15 interacts with host immune components?

Investigating interactions between ORF15 and host immune components requires a multidisciplinary approach:

• Protein-protein interaction identification:

  • Co-immunoprecipitation (Co-IP): Using specific antibodies against ORF15 or tags (FLAG, HA) in infected catfish cell lines, followed by mass spectrometry to identify co-precipitated immune proteins.

  • Yeast two-hybrid assays: Screening cDNA libraries from catfish immune cells against ORF15 as bait.

  • Proximity ligation assays (PLA): Detecting direct interactions in infected cells using specific antibodies and oligonucleotide probes.

  • BioID or TurboID: Fusion of biotin ligases to ORF15 to label proximal proteins in vivo, followed by affinity purification and proteomic analysis.

• Functional analyses of immune component modification:

  • In vitro phosphorylation assays: Incubation of purified ORF15 with candidate immune proteins and labeled ATP.

  • Phosphorylation site identification: Mass spectrometry analysis of immune proteins modified during infection.

  • Site-directed mutagenesis: Generation of mutants at identified phosphorylation sites to evaluate functional impact.

• Immune signaling pathway evaluation:

  • Reporter assays: Using reporter constructs (luciferase) under the control of relevant immune promoters (NF-κB, IFN-β) in presence/absence of ORF15.

  • Phosphoproteomics analysis: Global comparison of phosphoproteins in cells infected with wild-type versus ORF15 mutant viruses.

  • Western blotting for signaling markers: Monitoring activation of key components such as IRF3, STAT1, p38 MAPK in context of ORF15 expression/absence.

These complementary approaches would precisely determine whether and how ORF15 modulates host immune components during viral infection .